21:35 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma, colorectal cancer In vitro, cell culture and mouse studies identified an aminopyrimidine-based dual MAPK1/MAPK3 inhibitor that could help treat BRAF-mutant melanoma and colorectal cancer. Fragment-based screening, chemical synthesis and in vitro enzyme activity...
20:29 , Jul 6, 2018 |  BC Extra  |  Company News

Management tracks: Goldman Sachs, Acceleron

One of China's top healthcare analysts, Richard Yeh, said he is departing Goldman Sachs, where he was in global investment research for Asia Pacific. Several Asia-focused bankers and analysts, including Citigroup's Billy Cho, Bank of...
16:20 , May 23, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Animal models Mice treated prenatally with AMH could be used to screen therapies to treat polycystic ovary syndrome, a partially heritable disease. In blood samples from 66 pregnant patients with PCOS, AMH levels were higher...
23:25 , Jan 9, 2018 |  BioCentury  |  Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
15:01 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

FDA approves Aeterna's Macrilen

FDA approved a resubmitted NDA for Macrilen macimorelin acetate (Macrimorelin-GHST, AEZS-130) from Aeterna Zentaris Inc. (TSX:AEZS; NASDAQ:AEZS) for use in diagnosing adult growth hormone deficiency (AGHD). Aeterna plans to launch the oral ghrelin-mimetic growth hormone...
20:17 , Dec 21, 2017 |  BC Extra  |  Company News

Aeterna jumps on Macrilen approval

Aeterna Zentaris Inc. (TSX:AEZS; NASDAQ:AEZS) shares climbed Thursday after FDA approved a resubmitted NDA for Macrilen macimorelin acetate for use in diagnosing adult growth hormone deficiency (AGHD). Aeterna added C$0.91 (35%) to C$3.48 in Toronto, and...
23:41 , Dec 12, 2017 |  BC Extra  |  Company News

Management tracks: Achaogen, Minerva

Antibacterial company Achaogen Inc. (NASDAQ:AKAO) said Kenneth Hillan will step down as CEO, effective Jan. 1. He will remain president and president of R&D. Blake Wise, who has served as president and COO, will become...
04:07 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

EMA reviewing Aeterna Zentaris' Macrilen to evaluate AGHD

EMA accepted for review an MAA from Aeterna Zentaris Inc. (TSX:AEZS; NASDAQ:AEZS) for Macrilen macimorelin acetate (Macrimorelin-GHST, AEZS-130) to evaluate adult growth hormone deficiency (AGHD). A resubmitted NDA for the candidate is under FDA review for...
00:19 , Oct 20, 2017 |  BC Innovations  |  Product R&D

Fighting cancer by mouth

With its first compound through Phase I, Vaximm AG has started to unveil the data and technology behind its preclinical pipeline of oral cancer vaccines. Using an attenuated Salmonella strain, the company is building a...